Skip To Main Content
Lin Song on Muck Rack

Lin Song

As seen in: British Ecological Society (Wiley), Nature, Wiley, Wiley Online Library, arXiv, Memory Studies, PLOS ONE, Frontiers, Frontiers in Medicine, MDPI and

Get in touch with Lin

Contact Lin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Development and internal validation of a nomogram and machine-learning models for postoperative recurrence in adult patients with chronic rhinosinusitis with nasal polyps

|
By Lin Song, Xiaoli Zhang, Xia Deng, Xiaoli He, Hong Jiang, Lihua Yu, Hui Shi, Jingting Pi, Mingliang Feng
| Frontiers in Medicine
Abstract Background: Practical preoperative tools for estimating postoperative recurrence in chronic rhinosinusitis with nasal polyps (CRSwNP) remain limited. We developed and internally validated a conventional nomogram and multiple machine-learning models and evaluated the systemic coagulation–inflammation index (SCI) as a deterministic nonlinear composite of routine laboratory measurements. Methods: The analysis included 245 adults.
Open in Who Shared Issue with article?

Integrated lipidomics and fatty acid positional distribution for nutritional assessment of nine mammalian milks

|
By Meiqing Chen, Lin Song, Jun Zhang, Yingjie Qi, Xiaowei Zhao, Nan Zheng, Yangdong Zhang, Jiaqi Wang, Songcui Lu
| Nature Verified
Abstract The nutritional value of milk fat depends on lipid and fatty acid composition. This study characterized the lipidomics and fatty acid positional distribution of milk from nine mammalian species: cow, buffalo, yak, goat, sheep, camel, mare, donkey, and human. Lipid molecular species were profiled by liquid chromatography–tandem mass spectrometry.
Open in Who Shared Issue with article?

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial Original

|
By Jiajia Yuan, Jifang Gong, Zhi Peng, Tian Liu, Huiting Xu, Jianwei Yang, Jia Wei, Haiping Jiang, Yanhong Deng, Yusheng Wang, Changsong Qi, Cheng Lyu, Qiao Sun, Lin Song, Xiaotian Zhang, Lin Shen
| Nature Verified
Abstract FGFR2 has garnered attention as a promising therapeutic target for gastric cancer (GC) because of its role in GC progression. Infigratinib, an FGFR1–3 selective tyrosine kinase inhibitor, has shown potential in preclinical GC models. Infigratinib was evaluated in a phase 2 trial for patients with FGFR2-amplified GC or gastroesophageal junction (GEJ) adenocarcinoma who had failed two or more lines of systemic treatment for locally advanced or metastatic disease.
Open in Who Shared View Duplicates (2) Issue with article?
See all 58 licensed articles (67 Total)